The aim of this initiative is to create an annotated chemical-biological database that will be available to the scientific community, and which will enable access to its contents from other locations. In order to carry out this project, the ChemBioBank laboratory of the PCB, located at the Drug Discovery Platform (PDD), has a cold chamber which can hold the 50,000 compounds that it wishes to store. <\/p>\n
This laboratory also has a Liquid Chromatography\/Mass Spectrometry (LC\/MS) system for the analytic control of the library’s compounds, and a liquid handling device that will enable the distribution of compounds in solutions and plaques for experimental screening processes. The initiative aims to characterize the compounds in about 1,000 virtual trials and approximately 100 experimental trials which will be carried out in screening centers in Spain and Europe. <\/p>\n
The mission of the Drug Discovery Platform is to promote and add value to the research conducted at the Barcelona Science Park \u2013and, by extension in the UB group\u2013 in the areas associated with the discovery of new drugs. It applies its experience in the first stages of drug discovery \u2013 identification and validation of therapeutic targets, modular design, chemical discovery (hit finding) and optimization of compounds (lead optimization)- to achieve improvement in project quality and a possible reduction of the time and resources associated with the process spanning from the initial idea to the clinical phase. <\/p>\n","protected":false},"excerpt":{"rendered":"
Today Thursday, July 23rd, the Barcelona Science Park held the presentation ceremony of the new ChemBioBank laboratory, a Spanish initiative that aims to create an organized library of chemical compounds, mainly of academic origin, and their characterization via virtual and experimental screening methods. The general director of the Barcelona Science Park, Fernando Albericio, and representatives of the three institutions that promote the ChemBioBank – Jordi Quintana, manager of the Drug Discovery Platform (PDD) of the Barcelona Science Park (PCB) and coordinator of the project; Mabel Loza, coordinator of the Screening Platform, University of Santiago de Compostela (USC), and Ferran Sanz, director of the Biomedical Informatics programme of the Municipal Institute of Medical Research of Barcelona (IMIM)-, have participated in the event. <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-46309","post","type-post","status-publish","format-standard","category-uncategorized"],"acf":[],"yoast_head":"\n